معرفی
Dr. Scott Gettinger is a Professor of Internal Medicine (Medical Oncology) at Yale School of Medicine and Chief of Thoracic Medical Oncology. He specializes in lung cancer treatment and research, focusing on immunotherapy and targeted therapies for non-small cell lung cancer. His work emphasizes understanding mechanisms of treatment sensitivity and resistance. He leads multiple clinical trials evaluating novel therapies, including combinations of immunotherapies and targeted agents.
Education: MD from Brooklyn College (1999), BS from Trinity College (1991). Completed residency and fellowship at Beth Israel Medical Center, NY.
Research Interests: Immunotherapy, targeted therapy, lung cancer biology, clinical trials, molecular mechanisms of drug resistance. Key collaborations include work with the Stephen & Denise Adams Center for Parkinson’s Disease Research and Yale Cancer Center.
Clinical Trials: Sub-investigator in trials such as the Phase III Lung-MAP S1400I study and trials evaluating NC318, lifileucel, and Brigatinib. Focus on biomarker-driven therapies and translational research.
Affiliations: Yale Cancer Center, SPORE in Lung Cancer, Developmental Therapeutics Program. Recognized internationally for contributions to thoracic oncology.